| abstract |
The present invention relates to a novel benzylamide derivative of formula (I), a process for the preparation of said compound; Pharmaceutical compositions comprising said compounds, and pathological conditions or diseases that can be ameliorated by inhibition of transforming growth factor-β receptor I (TGFβRI)/ALK5, such as fibrotic conditions of the gastrointestinal system, skin and eyes. A therapeutically effective amount of said compounds, methods of treating and/or preventing said diseases or pathological conditions, and other therapeutic agents comprising said compounds, useful for treating said diseases or pathological conditions It relates to a combination further comprising: . |